Do particles hold the power to pave the way for new drugs? In this interview, we speak to Ben Knappett, head of science and applications at Particle Works to find out more!
The COVID-19 pandemic brought lipid nanoparticles (LNPs) to prominence, with multiple pharmaceutical manufacturers – including Moderna and Pfizer-BioNTech – rapidly developing mRNA-LNP vaccines that were administered globally. The success of these vaccines has firmly established the potential of this technology to help treat a broad scope of diseases and illnesses, especially using gene therapy approaches, where LNPs are already demonstrating promise as non-viral delivery vectors. How
Particle Works continues to pave the way for particle perfection with the highly anticipated launch of its second revolutionary platform, the Automated Library Synthesis (ALiS) System. This innovative platform enables automation and high-throughput screening of lipid nanoparticle (LNP) formulations and mRNA candidates in early-stage drug development.
Dolomite Microfluidics, a leading developer of particle systems for drug delivery, and Phosphorex, Inc., a leading contract development and manufacturing organization specializing in particle-based formulation of drug products, are pleased to announce their partnership to establish unique capabilities in drug and vaccine development.